The research compound in Contrave^®

Contrave^® is a weight management medicine from Currax Pharmaceuticals. Its active compound is Naltrexone/Bupropion — which is what this catalogue supplies, as a research material.

This is not Contrave^®, and NOVALYTE LABS has no affiliation with Currax Pharmaceuticals. We supply the compound Naltrexone/Bupropion for laboratory research only — not for human consumption, diagnostic, therapeutic or veterinary use. Contrave^® is a trademark of Currax Pharmaceuticals, referenced here only to identify the compound.

Contrave is the United States brand for the naltrexone and bupropion combination, marketed as Mysimba in Europe.

The two agents act on central pathways rather than on gut hormones, which places it outside the GLP-1 class entirely.

The combination is listed here as a research material with batch documentation.

Naltrexone/Bupropion in this catalogue

Other brands using Naltrexone/Bupropion

The same compound is marketed under more than one brand, usually because each brand carries a different approved indication.